Exploratory Study of Personalized mRNA Vaccine in Patients With Refractory Rhabdomyosarcoma

Xinxin Zhang

Status and phase: Not yet enrolling; Early Phase 1

Conditions: Rhabdomyosarcoma

Treatments: Biological: mRNA Tumor Vaccine Therapy

Study type: Interventional

Funder types: Other

Identifiers

NCT06932861

PRRR Study

Details and patient eligibility

About

An Exploratory Study on the Use of mRNA Tumor Vaccines in the Treatment of Refractory Rhabdomyosarcoma

Enrollment: 5 estimated patients

Sex: All

Ages: 6+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Diagnosed with rhabdomyosarcoma confirmed by pathological or molecular testing;
2. Age ≥ 6 years;
3. No known effective treatment available or no treatment proven to prolong survival with an acceptable quality of life;
4. Expected survival time greater than 6 months;
5. ECOG performance status score of 0-1; -

Exclusion criteria

• 1.History of or concurrent with other untreated malignant tumors, except for previously cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and superficial bladder cancer; 2.History of or current active autoimmune diseases. 3.Has uncontrolled cardiovascular diseases.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

5 participants in 1 patient group

Vaccine arm

Experimental group

Treatment:

Biological: mRNA Tumor Vaccine Therapy